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Abstract 
 
Metastatic lesions of renal cell carcinoma (RCC) occasionally regress spontaneously after 
surgical removal of the primary tumor. Although this is an exceptionally rare occurrence, 
RCC has thus been postulated to be immunogenic. Immunotherapies, including cytokine 
therapy, peptide-based vaccines, and immune checkpoint inhibitors have therefore been 
used to treat patients with advanced, metastatic RCC. We review the history, trends, and 
recent progress in immunotherapy for advanced RCC and discuss future perspectives, with 
consideration of our experimental work on galectin 9 and PINCH as promising specific 
immunotherapy targets. Copyright: The Authors. 
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Introduction 
 
Metastatic lesions of renal cell carcinoma 
(RCC) occasionally regress spontaneously 
following removal of the primary disease, 
though this is exceptionally rare. This is 
thought to represent an immune response, 
and RCC, like melanoma, has thus been 
considered to be immunogenic. Although 
very few urologists have been fortunate 
enough to experience such a rare event, 
these anecdotes suggest that RCC may be 
immunogenic in nature. Before the era of 
molecular targeting drugs, cytokine therapy 
with interferon (IFN) or interleukin-2 (IL-2) 
was widely used, and partial response (PR) 
and complete response (CR) were achieved 
in 15.9% and 1.8%, respectively, of 
patients with advanced RCC treated with 
IFN (1). Despite the low response rate, it is  
 
noteworthy that cytokine therapy can 
achieve a CR or cure in patients with 
advanced metastatic RCC. 
 
Furthermore, even though prostate cancer, 
unlike RCC, is not generally described as 
immunogenic, we experienced a patient 
with castration-resistant prostate cancer 
(CRPC) with bone metastases who 
maintained CR for a long period after 
hormonal manipulation and chemotherapy 
with docetaxel. In another case of CRPC, 
the tumor was reported to vanish 
spontaneously during therapy (2). These 
outcomes could be attributed to an 
immune response. These rare but 
important clinical observations suggest 
that specific cancer immunity can be 
triggered by certain conditions, and that 
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cancer immunity has the potential to 
achieve a cure in some cases. 
Immunotherapy has thus been a focus of 
research for advanced RCC, even in the era 
of molecular targeting drugs.  
 
History of therapies for RCC 
 
The history of therapies for RCC is 
summarized in Table 1 (3). IFNα and IL-2 
were approved in Japan in 1987 and 1999, 
respectively, and reduced-intensity stem 
cell transplantation (RIST) was reported by 
Child et al. (4) in 2000. This ‘mini-
transplantation’, aimed to damage tumor 
cells via a graft versus host reaction, was 
expected to demonstrate good clinical 
efficacy; however, the results in Japan have 
been disappointing (5). 
 
Identification of the von Hippel-Lindau 
(VHL) tumor suppressor gene in 1993 (6) 
and subsequent discovery of a high rate of 
VHL gene mutations in patients with 
sporadic RCC (7) formed the theoretical 
basis for molecular targeting drugs for 
advanced RCC, such as tyrosine kinase 
and mammalian target of rapamycin 
inhibitors. The VHL gene product functions 
as an ubiquitin ligase targeting hypoxia-
inducible factor-1α (HIF-1α). HIF-1α levels 
are regulated by its degradation in the 
ubiquitin/proteasome system. Excess HIF-
1α caused by malfunctioning of the VHL 
protein results in up-regulation of vascular 
endothelial growth factor (VEGF) and 
glucose transporter-1, which are 
responsible for the characteristic RCC 
phenotypes of hypervascularity and clear 
cytoplasm on hematoxylin and eosin 
staining, respectively. 
 
Molecular targeting drugs target the 
cascade mediated by VHL protein, and 
several such agents, including sorafenib, 
sunitinib, axitinib, temsirolimus, and 
everolimus, have been approved in Japan 
since 2008. 
 
Therapeutic approaches for RCC: 
immunotherapy and molecular targeting 
drugs 
 
The extremely rare spontaneous regression 
of metastatic lesions following surgical 
removal of the primary lesion, e.g., by 
nephrectomy, is thought to be caused by 
an immunologic response. This 
characteristic of RCC and the consequent 
notion that RCC is immunogenic, form the 
basis for non-specific immunotherapy with 
cytokines, which has been employed for 
some time. However, molecular targeting 
drugs currently form the mainstream of 
treatment for metastatic RCC. The use of 
IFNα is currently limited to lung 
metastases. In this review, we consider 
recent progress in immunotherapy for RCC 
and discuss future prospects with regard to 
the role of immunotherapy as a 
mainstream therapy for RCC. 
 
Overview of cytokine therapy for 
advanced, metastatic RCC 
 
Urologists have continued to treat patients 
with advanced metastatic RCC using IFNα 
for the past 20 years. Although a previous 
study reported response rates to IFNα as 
low as 15.9% and 1.8% for PR and CR, 
respectively (1), it is noteworthy that 
cytokine therapy resulted in some 
instances of CR, which were not achieved 
with molecular targeting drugs. 
Furthermore, a Japanese multicenter study 
reported a survival benefit of cytokine 
therapies in RCC patients with lung 
metastases (8). Cytokine therapy may thus 
be generally beneficial in many patients 
with RCC. The combination of IFN and IL-2 
resulted in response rates of 35.7% and 
4.8% for CR+PR and CR, respectively, 
indicating further possibilities of cytokine 
therapy (9). 
 
The anti-tumor mechanisms of IFN involve 
activation of macrophages and monocytes, 
enhancement of natural killer (NK) cell 
activities, induction of antigen presentation 
on the cell surface, and enhancement of 
cytotoxic T lymphocyte (CTL) activities (10). 
Although IL-2 enhances the activities of NK 
cells, B cells and T cells, including CTLs, it 
also temporarily activates regulatory T cells 
(Tregs) via the IL-2 receptor α-chain on 
Tregs, and may thus suppress CTL 
activities with possible unfavorable effects. 
 
Peptide-based vaccines 
 
Peptide-based vaccines represent a rational 
approach to inducing cancer-specific 
immunity against cancer antigens. Tumor-
associated antigens (TAA) are incorporated 
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      Table 1. History of therapy for renal cell carcinoma (Revised from 3) 
Year Notable Events 
1963 Radical nephrectomy 
1987 IFN-α approved (in Japan) 
1990~ Partial nephrectomy for small RCC 
1993 
Identification of von Hippel-Lindau tumor suppressor gene: rationale for 
molecular targeting drugs 
1999 IL-2 approved (in Japan) 
2000 
‘Mini-transplantation’ (reduced-intensity stem cell transplantation; RIST) for 
treatment of RCC 
2002 Laparoscopic nephrectomy approved (in Japan) 
2008 Molecular targeting drugs approved (in Japan) 
 
 
into antigen-presenting cells (APCs), 
broken down into pieces, processed, and 
presented on HLA class I (MHC class I) in 
the form of peptides. The presented peptide 
antigens stimulate CD8+ effector cells 
(CTLs) that specifically recognize the 
antigen and attack cancer cells bearing the 
TAA. The amino acid sequences of the 
peptides within TAA sequences have been 
investigated with the aim of producing 
peptide-based vaccines. Candidate peptides 
capable of binding HLA class I are 
synthesized and used to stimulate 
peripheral blood mononuclear cells in vitro 
to induce antigen-specific CTLs. Peptides 
capable of inducing CTLs with high, 
specific cytotoxic activity toward cancer 
cells are then selected for use as vaccines. 
These peptides, mixed with adjuvant, are 
presented on HLA class I of APCs following 
injection, resulting in lymphocyte 
stimulation and induction of tumor 
antigen-specific CTLs.  
 
Regarding the clinical efficacy of peptide-
based vaccines for RCC, Uemura et al. (11) 
reported three PR and six stable diseases 
(SD) among 23 patients with metastatic 
disease in a phase I trial of carbonic 
anhydrase 9-derived peptides. Limited 
efficacy (SD) was achieved following 
immunotherapy using Wilms’ tumor 1 
peptide in two of three RCC patients 
enrolled in one study (12). Hypoxia-
inducible factor prolyl hydroxylase 3 
(HIFPH3) was shown to be over-expressed 
in primary RCC tissues and many RCC cell 
lines, and an HIFPH3-derived peptide 
induced CTLs in three of six RCC patients, 
though no clinical trials have been reported 
(13).  
 
A phase II randomized, clinical trial of 
IMA901, a mixture of multiple TAA-derived 
peptides, showed that Tregs were reduced 
by a single dose of cyclophosphamide, and 
patients responded immunologically to 
IMA901 had longer overall survival (14). A 
phase I clinical trial of human VEGF 
receptor 1-derived peptide vaccines in 
patients with metastatic RCC demonstrated 
PR in two and SD for more than 5 months 
in eight of 18 patients (15).  
 
Peptide-based vaccine therapy emulates 
naturally occurring antigen presentation, 
and targets specific cellular immunity 
against cancer cells using TAA-derived 
peptides. Peptide vaccine therapy is thus 
rational with the potential for high efficacy. 
However, it has so far demonstrated limited 
clinical effects in patients with metastatic 
RCC, probably because of the lack of 
defined, appropriate antigens. 
 
Innate and acquired immune systems in 
cancer immunotherapy 
 
The innate immune system seems to play 
an important role in the initial stages of 
anti-cancer immunity. Concerning the 
implications of innate immunity for 
immunotherapy of RCC, several reports 
have focused on NK cells. Combination 
therapy with IFNα and IL-2 has been 
reported to enhance the cytotoxic activities 
of NK cells in patients with advanced RCC 
(16) and NK cells have been shown to be  
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Figure 1. Antigen-specific, HLA-A*2402-restricted cytotoxicities of CTLs induced with galectin 9-
derived (A) and PINCH-derived peptides (B). A, B. Peripheral blood mononuclear cells from healthy 
volunteers (HLA-A*2402) were stimulated with galectin 9-derived and PINCH-derived peptides, 
respectively, to induce CTLs. The cytotoxicity of the CTLs toward RCC cells was assessed by a 51Cr-
release assay (21).CTLs induced by both peptides showed high cytotoxic activity toward TUHR-10TKB 
RCC cells (HLA-A*2402+, galectin 9+, PINCH+) and SKGIIIa uterine cancer cells (HLA-A*2402+, 
galectin 9+, PINCH+). CTLs were not active toward cells with different HLA-A or negative antigens. 
Bars represent means±standard errors of assays performed in triplicate. A. CTLs induced by the 
galectin 9-derived peptide exhibited cytotoxicity toward OCUU-1 RCC cells (HLA-A*0206+, galectin 
9+), implying less stringency in terms of HLA-A for the CTLs used. 
 
 
necessary for anti-tumor activities in RCC 
patients treated with cytokines (17). 
Furthermore, low numbers of peripheral 
NK cells (NK-Kir+) correlated with shorter 
disease-free survival in patients with RCC 
(18).  
 
NKT cells also contribute to anti-cancer 
immunity, and a lack of these cells is 
associated with impaired anti-cancer 
immunity (19). The exogenous NKT cell 
ligand α-galactosylceramide was tested in a 
clinical trial for lung cancer and head and 
neck cancer (20). NKT cells are activated as 
follows: Toll-like receptors activate 
dendritic cells to produce IL-2. Stimulation 
by IL-2 and recognition of a self-ligand 
presented on CD1d of APCs then cause 
activation of NKT cells, which in turn 
activate specific helper T cells, together 
with CD8+ CTLs. The NKT cell system thus 
acts as a functional bridge between the 
innate and acquired immune systems in 
the development of specific immunity. The 
innate immune system, represented by the 
NK and NKT systems, thus provides an 
initial step in anti-cancer immunity 
eventually leading to acquired and cancer-
specific immunities. 
 
It is likely that the development of specific 
and effective immunity against RCC could 
achieve a cure, though no effective means 
of achieving this goal have yet been 
identified. 
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Galectin 9 and PINCH: isolation and 
evaluation of new tumor antigens for 
peptide-based vaccine therapies 
 
Despite a low response rate, cytokine 
therapy can offer an effective therapeutic 
option for advanced RCC. Survival benefit 
of cytokine therapy has been reported in 
patients with metastatic RCC (8), and the 
observation that cytokine therapy can 
induce a CR in a very limited number of 
patients with metastatic RCC indicates the 
curative potential of immunotherapy. The 
key to understanding the successful 
induction of anti-cancer immunity involves 
knowing which antigens are important and 
how specific immunity is acquired in those 
few patients who respond well to cytokine 
therapy. It is also important to establish if 
the mechanisms of specific immunity in 
those successful cases are applicable to 
RCC patients in general. If so, general 
methods for inducing cancer immunity 
based on these specific cases may provide 
effective and potentially curative therapies 
for patients with advanced RCC. This could 
reduce the need for expensive, molecular 
targeting drugs, thus helping to limit the 
expanding medical expenditure in Japan. 
 
We investigated ‘true cancer antigens’ by 
screening an RCC expression library using 
sera from patients with metastatic disease 
who responded well to cytokine therapy as 
probes, under the assumption that these 
responders had acquired specific 
antibodies against RCC together with 
specific cellular immunity. We identified 
two novel genes, galectin 9 and PINCH, as 
RCC-specific antigens that were specifically 
highly expressed in all the tested clear cell 
carcinoma samples, compared with normal 
renal tissues (21). Using peptides derived 
from these two antigens, we induced HLA-
A*2402-restricted CTL clones and HLA-
A*0201-restricted CTLs with high antigen-
specific killing activities toward RCC cells 
(21) (Figure 1). These antigens seemed to 
be closely related to an immune escape 
mechanism, cancer cell survival, and 
metastases of RCC. 
 
Galectin 9 modulates cellular immunity by 
suppressing excess immune reactions such 
as allergies. Its receptor is T cell 
immunoglobulin and mucin domain 3 
(TIM-3), located on the surface of T cells. 
Galectin 9 causes apoptosis of activated T 
cells through TIM-3 (22, 23), which is an 
immune checkpoint molecule, as are 
programmed cell death protein-1 (PD-1) 
and CTL-associated protein 4 (CTLA-4) 
(24). These immune checkpoint molecules 
mediate immunosuppressive signals 
causing inactivation of T cells. Anti-cancer 
drugs targeting these immune checkpoints 
are currently under development, and have 
attracted considerable attention and 
expectations (25). 
 
PINCH contributes to apoptosis resistance 
in cancer cells (26) and promotes epithelial-
mesenchymal transition in renal tubular 
cells (27), and thus plays an important role 
in cancer survival and metastases. 
 
Galectin 9 and PINCH produce favorable 
environments for RCC cells and therefore 
provide promising targets for 
immunotherapy. Our method of identifying 
potentially useful cancer antigens was 
unique in that we screened for antigens 
with central roles in developing specific 
anti-cancer immunity by reacting them 
with sera from responders to cytokine 
therapy. The abilities of the identified 
antigens to induce CTLs with specific, high 
cytotoxicity was then evaluated. This 
method involved basic molecular cloning 
techniques using clinical samples, and was 
developed by a urologist with extensive 
experience, including many clinical cases of 
RCC (21). 
 
Peptide-based vaccines have the problem 
that various peptide sequences of the same 
antigen need to be prepared in accordance 
with the HLA types of the patients. TAAs 
are presented on HLA class I in a form of 
peptides that comprise part of the whole 
antigen: different peptides derived from the 
same whole antigen associate with HLA 
class I of different HLA types. The binding 
motif of the antigen for each HLA type 
should be predicted in silico, and the 
ability of each predicted peptide to induce 
CTLs by stimulating lymphocytes of the 
same HLA type needs to be tested. We 
previously identified galectin 9- and 
PINCH-derived peptides that induced HLA-
A*02-restricted CTLs, HLA-A*24-restricted 
CTLs, and HLA-A*33-restricted CTLs (28), 
respectively, all of which exhibited specific 
and highly cytotoxic activities toward RCC 
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Table 2. Anti-cancer drugs targeting immune regulatory checkpoints (Revised from 3) 
Drug Target Cancer Type 
Phase of 
clinical trial 
Ipilimumab 
CTLA-4 
(antibody) 
Melanoma Approved 
Tremelimumab 
CTLA-4 
(antibody) 
Hepatocellular 
carcinoma (hepatitis 
C) 
II 
Nivolumab (BMS-936558) 
MDX-1106 
ONO-4538 
PD-1  
(antibody) 
RCC, melanoma, 
NSCLC* 
III 
MEDI-4736 (Zeneca) 
PD-L1 
(MAb) 
Solid tumors II (lung) 
MEDI-6469 (Zeneca) 
OX-40 
(activation: 
agonistic 
antibody) 
Solid tumors I 
MPDL-3280A (Genentech) 
PD-L1 (Mab, 
humanized) 
NSCLC, melanoma, 
RCC 
II (NSCLC) 
*NSCLC, non-small cell lung cancer. 
 
 
cells. The frequency of HLA-A*02 is high in 
Europe and North America, while HLA-
A*24 is a major HLA type, and HLA-A*33 is 
also common in Japan. These peptides 
thus represent important candidates for 
future peptide-based vaccine therapies. 
 
New anti-cancer drugs targeting immune 
checkpoint molecules 
 
Cancer cells have recently been shown to 
exploit immune checkpoint molecules that 
mediate the suppression of immune 
signals, thus facilitating escape from the 
immune surveillance system. These 
checkpoint molecules, including CTLA-4, 
PD-1, programmed death ligand 1 (PD-L1), 
and TIM-3, mediate T cell suppression. 
Drugs (antibodies) targeting these check 
point molecules, referred to as check point 
inhibitors, including antibodies against 
CTLA-4, PD-1, and PD-L1, have been 
developed (25) and in some cases approved 
(Table 2). 
 
Clinical studies of an anti-PD-1 antibody 
(nivolumab; BMS-936558) (29, 30) and a 
humanized monoclonal antibody against 
PD-L1 (MPDL-3280A) (30) have been 
reported in patients with RCC. A response 
rate (PR + CR) of 27% was achieved with 
nivolumab in patients with RCC (29). 
 
Increasing attention has been paid to TIM-
3 as a target (24). TIM-3 binds to its ligand 
galectin 9, causing suppression of activated 
T cells (22, 23). Combined therapy with 
anti-TIM-3, anti-PD-1, and anti-CTLA-4 
antibodies demonstrated an additive anti-
tumor effect in experimental animal models 
(31). Our study suggested that galectin 9-
derived peptides would induce CTLs that 
attack RCC, and also remove the 
immunosuppressive environment caused 
by activation of the immune checkpoint 
TIM-3. 
 
Summary 
 
Progress in molecular biology following the 
discovery of the VHL gene has resulted in 
the development of various molecular 
targeting drugs and advancements in 
therapies for advanced RCC. On the other 
hand, following on from the long-standing 
use of cytokines such as IFN and IL-2, 
immunotherapy is about to enter a new era 
represented by immune checkpoint 
inhibitors. However, the costs associated 
with the clinical study, development, and  
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approval of these immune checkpoint 
inhibitors, marketed as humanized 
antibodies, are likely to be enormous. 
 
Peptide-based vaccine therapy aims to 
induce specific immunity, and appears to 
offer potential survival benefits and cure; 
however, their efficacy is currently poor. 
Innate immunity provides an initial step 
leading to specific anti-cancer immunity, 
and non-specific immune reactions 
initiated by cytokines may also cause 
specific anti-tumor immunity. The 
combination of ‘real’ cancer antigens and 
new, immune-activating agents targeting 
molecules such as immune checkpoints 
may thus induce strong cancer-specific 
immunity. 
 
Cytokine therapy is highly effective in a 
very limited number of patients, indicating 
the high potential of immunotherapy. 
However, the mechanisms responsible for 
the development of immunity in these 
patients with RCC remain unclear. We 
identified novel RCC antigens that reacted 
with sera from cytokine-therapy 
responders. We successfully induced 
antigen-specific, HLA-restricted CTLs with 
high activities by stimulating lymphocytes 
with peptides derived from those antigens. 
However, the mechanisms responsible for 
the effects of the cytokines in particular 
cases are unknown. Further, detailed 
investigations of successfully treated cases 
and analysis of the general mechanisms 
are likely to lead to promising new 
therapies for RCC. 
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